Imdelltra Amgen Australia Pty Ltd
Product name
Imdelltra
Sponsor
Accepted date
Jul-2024
Active ingredients
tarlatamab
Proposed indication
Treatment of adult patients with advanced small cell lung cancer.
Application type
A (new medicine)
Publication date
Jul-2024
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration.